The online hub for digital CME and CE courses
The ONA Forum consultants answer your questions
View articles about patient-focused care
February 25, 2013
In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Use of the oral antidiabetes drug metformin improved survival in women with ovarian cancer, according to the findings of a retrospective case-control study.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Inhibiting one protein eliminated metastasis of melanoma in lab studies, a finding that could lead to targeted therapies for a range of cancers.
The ability to detect cancer DNA in the blood has been combined with genome sequencing technology in a test that could be used to screen for cancers, monitor cancer patients for recurrence, and find residual cancer left after surgery.
Excessive levels of interleukin-15 initiate large granular lymphocyte (LGL) leukemia, but also represent a promising therapeutic target.
The mTOR inhibitor dramatically reduced the volume of subependymal giant cell astrocytomas (SEGAs) in persons with tuberous sclerosis complex.
Gemtuzumab ozogamicin, discontinued here in 2010, reduced relapse risk and improved survival in Welsh patients with acute myeloid leukemia.
Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.
Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.
Persons with glioblastoma who undergo repeated resections can have improved survival, indicate the findings of a recent study.
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Positron emission tomography (PET) can non-invasively predict how much of a cancer-killing drug is absorbed by a tumor. This preliminary study, conducted in lung cancer patients, found that less than 1% of docetaxel is absorbed by the tumors.
Combining trastuzumab and lapatinib with an anti-VEGFR2 antibody dramatically improved survival in HER2 breast cancer with brain metastases.
Levels of circulating tumor cells and of prostate specific antigen were reduced by a new drug in patients who had already failed previous chemotherapy and hormone treatments.
Many persons who receive chemotherapy for incurable cancers may not understand that the treatment is unlikely to be curative.
Two separate research teams identified genes that can predict outcomes in men with castration-resistant prostate cancer (CRPC).
Administering radiotherapy after prostatectomy helped nearly two-thirds of users in a recent study remain free of prostate cancer after 10 years.
A combination of chemotherapy and immunotherapy appears to be a labor-intensive but feasible treatment for persons with metastatic melanoma.
An intrauterine device releasing the progestin levonorgestrel was effective therapy for early endometrial cancer in women not fit for surgery.
A therapeutic vaccine for women who are already harboring human papillomavirus (HPV) appeared to fight cervical cancer in a small, phase 1 study.
Scientists discovered PARP-1 contributes to the growth and progression of androgen receptor-positive prostate cancer cells.
Nelfinavir, a protease inhibitor used in the treatment of HIV, has been found to inhibit the growth of HER2-positive tumors in mice.
New insights into the action of taxanes on androgen receptors in prostate cancer shed light on why a patient may not respond to these drugs.
October 26, 2012
Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.
October 26, 2012
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Two drugs under FDA evaluation slowed treatment resistance in persons with metastatic malignant melanoma positive for the BRAF protein.
A protein that confers a worse prognosis in bladder cancer when present in high levels may respond to antiandrogen therapy used in prostate cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |
